Trial Profile
A phase IIb study of MSDC-0602 in non-alcoholic steatohepatitis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2015
Price :
$35
*
At a glance
- Drugs Azemiglitazone (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 10 Feb 2015 Metabolic Solutions development company plans to initiate this study in 2015.
- 10 Feb 2015 New trial record